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PPAD remains a credible candidate for
inducing autoimmunity in rheumatoid arthritis:
comment on the article by Konig et al
There is accumulating evidence that periodontitis is linked to
rheumatoid arthritis (RA) and that this may be due to the patho-
gen Porphyromonas gingivalis possessing a peptidyl arginine dei-
minase (PPAD). This apparently unique bacterial enzyme is
capable of producing citrullinated bacterial or host proteins
which could break tolerance leading to the generation of auto-
antibodies in RA.1 We have previously shown that PPAD is auto-
citrullinated and there is an increased antibody response to
PPAD in RA, which was due to reactions with autocitrullinated
epitopes on the PPAD molecule.2 We were therefore interested
to read the article by Konig et al3 in which they confirm our
findings that full-length recombinant PPAD is autocitrullinated,
but showed that a truncated and secreted form of PPAD purified
from supernatants of P. gingivalis cultures was not autocitrulli-
nated. From this they concluded that autocitrullination was a
feature of cloning, which would not occur in nature. However,
growing bacteria in culture is not natural either. In vivo, at the
site of infection, bacteria would be lysed by the immune
response and bacterial proteins, including PPAD, potentially
citrullinated by PPAD itself, or by host deiminases such as
PAD2, and exposed to the immune system.
The bulk of Konig et al’s report was devoted to their finding
that there was no citrulline-specific antibody response to their
form of autocitrullinated full-length PPAD in patients with RA.
This was in complete contrast to our own finding of raised anti-
body levels to autocitrullinated PPAD in 25% of patients with
RA. The reason for this discrepancy is unknown, though it is
well known that citrullinated antigens in the form of whole pro-
teins do not perform reproducibly in ELISA assays. Accordingly,
in our original study we went on to test antibodies to synthetic
peptides spanning the length of PPAD with all arginines substi-
tuted with citrullines.2 We found antibodies to three immunodo-
minant citrulline-specific epitopes (designated CPP3, CPP5 and
CPP8) with diagnostic sensitivities ranging from 15% to 40% in
RA sera.
In the current study, we examined 284 serum samples from
patients with well documented RA compared with 330 osteo-
arthritis (OA) controls from a previously published cohort,4
using the CPP3 (CAKTDSYWT-Cit-DYTGWFAMYDC) peptide,
with a citrulline at position R129, together with its correspond-
ing arginine-containing control peptide (RPP3). Importantly,
this specific residue was demonstrated by mass spectrometry to
be autocitrullinated in Konig et al’s study. Antibodies to CPP3
were significantly elevated in the anti-cyclic citrullinated peptide
antibody (anti-CCP) positive RA serum samples with no signifi-
cant increase in antibody levels to the control peptide (figure
1A, B). By plotting the correlation between antibodies to CPP3
and RPP3, it can be clearly seen that approximately 15% of the
anti-CCP positive RA serum samples react preferentially with
citrulline-containing epitopes, as indicated by the points above
the regression line (figure 1C). This citrulline-specific reactivity
Figure 1 Antibodies to citrullinated peptidyl arginine deiminase (PPAD) peptide (CPP3) and uncitrullinated PPAD peptide (RPP3) in serum of
patients with rheumatoid arthritis (RA) and controls with osteoarthritis (OA). Antibodies to (A) CPP3 and (B) RPP3 in OA controls, anti-CCP negative
RA and anti-CCP positive RA. The grey lines indicate median reactivity for each group. Mann-Whitney U test was used to calculate p values for
differences between the groups (n.s.=no significant difference, *p<0.05 and **p<0.01, ***p<0.001). (C) Spearman correlation of anti-CPP3 and
anti-RPP3 in anti-CCP positive RA, (D) in anti-CCP negative RA and (E) in OA controls.
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was not seen with the anti-CCP negative serum samples or with
the OA controls (figure 1D, E). Similar findings of a citrulline-
specific antibody response to CPP3 were found in a Swedish
study of 200 patients with RA and 100 controls, presented at the
2013 American College of Rheumatology meeting.5 These results
are in contrast to the findings of Konig et al who showed an
almost perfect correlation between binding to autocitrullinated
whole PPAD and the uncitrullinated mutant control in RA.
Therefore we argue that it is premature to claim that: “PPAD
autocitrullination is not the underlying mechanism linking peri-
odontitis to RA”.3 The ELISA used by Konig et al was clearly
not detecting antibodies to citrullinated epitopes on PPAD, and
importantly, their results were not confirmed using peptide
ELISAs. We suggest that PPAD remains a credible candidate for
inducing an antibody response to citrullinated proteins in RA—
be it through autocitrullination, citrullination by human PAD
enzymes, or citrullination of other bacterial and/or human
proteins.
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